In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

A boxed warning for testosterone on major adverse cardiovascular events is out and a new blood pressure warning is in, the ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Deprescribing antihypertensive medication is not associated with the risk for hospitalization for myocardial infarction (MI) or stroke in long-term care residents, according to a study published ...

A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic stroke on top of its ...

HealthDay News — Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction, according to a study published online Feb. 12 in ...

For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium ...